Healthcare Services

An Important Factor Driving the Candidiasis Therapeutics Market Is the Rising Clinical Trials Fueling Advancements In Candidiasis Therapeutics Market

March 30, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Increase Is Anticipated For The Candidiasis Therapeutics Market Over The 2026–2030 Period?

The candidiasis therapeutics market has experienced consistent expansion in its size during recent years. It is projected to increase from $3.29 billion in 2025 to $3.4 billion in 2026, achieving a compound annual growth rate (CAGR) of 3.5%. The historical growth can be attributed to several factors, including an escalating prevalence of immunocompromised patient populations, a growing incidence of hospital-acquired fungal infections, the widespread adoption of broad-spectrum antibiotics, the availability of well-established antifungal drug classes, and the expansion of hospital-based infectious disease care.

The candidiasis therapeutics market is projected to experience consistent expansion over the coming years, anticipated to reach $4.03 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 4.3%. Factors contributing to this growth during the projection period include more extensive research into new antifungal drug categories, heightened awareness regarding the management of antifungal resistance, wider acceptance of outpatient antifungal treatments, an increased emphasis on therapies for pediatric candidiasis, and greater investments in developing drugs for infectious diseases. Key trends foreseen for this period encompass the accelerated development of targeted antifungal treatments, a stronger emphasis on prompt and precise diagnosis, an uptick in the utilization of combination antifungal therapies, a broader range of oral and systemic treatment choices, and improved surveillance of drug resistance profiles.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13182&type=smp

What Drivers Are Expected To Influence The Candidiasis Therapeutics Market During The Forecast Period?

The growing volume of clinical trials is anticipated to advance the candidiasis therapeutics market moving forward. These trials are research studies conducted to assess the safety and efficacy of new medical treatments, interventions, drugs, or devices in humans. They play a crucial role in the development of candidiasis therapeutics by establishing a systematic and rigorous process for evaluating the safety and effectiveness of potential treatments. For instance, in May 2023, information from ClinicalTrials.gov, which is part of the National Institutes of Health (NIH), a US-based government agency responsible for conducting and supporting medical research, revealed that approximately 437,533 clinical trials were registered in 2023, compared to 399,499 registered studies in 2022, across all 50 states of the United States and in 221 countries. Thus, the increasing number of clinical trials is indeed fueling the expansion of the candidiasis therapeutics market.

How Is The Candidiasis Therapeutics Market Segmented Across Key Categories?

The candidiasis therapeutics market covered in this report is segmented –

1) By Treatment Type: Medication, Supportive Therapy

2) By Anatomy Type: Oral Candidiasis, Vulvovaginal Candidiasis, Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis

3) By Mode Of Administration: Injectable, Oral, Other Mode Of Administrations

4) By Patient Population: Adults, Pediatrics

5) By End User: Hospitals, Specialty Clinics, Other End Users

Subsegments:

1) By Medication: Antifungal Drugs, Topical Treatments, Systemic Treatments

2) By Supportive Therapy: Probiotics, Symptom Management Therapies, Adjunct Nutritional Support

Which Upcoming Trends Are Expected To Influence The Candidiasis Therapeutics Market?

Companies actively involved in the Candidiasis Therapeutics market are prioritizing the development of innovative solutions, such as echinocandin antifungal therapy, to enhance treatment effectiveness, mitigate resistance, and improve patient outcomes in the management of invasive and systemic Candida infections. Echinocandin antifungal therapy is a class of medications that suppresses ß-(1,3)-D-glucan synthesis in fungal cell walls, thereby effectively treating severe invasive Candida infections. For example, in March 2023, Cidara Therapeutics Inc., a US-based biotech company, in partnership with Melinta Therapeutics, a US-based biopharmaceutical company, obtained U.S. FDA approval for REZZAYO (rezafungin for injection) specifically for treating candidemia and invasive candidiasis in adults with limited or no other treatment options. REZZAYO stands as a novel once-weekly echinocandin antifungal, representing the first new therapeutic choice for these infections in over a decade.

Who Are The Dominant Players Shaping The Candidiasis Therapeutics Market Landscape?

Major companies operating in the candidiasis therapeutics market are Pfizer Inc., Biocon Limited, Torrent Pharmaceuticals Ltd., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc, GSK plc, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Cipla Inc., Lupin Limited, Basilea Pharmaceutica Ltd., WOCKHARDT Limited, Cidara Therapeutics Inc., Amplyx Pharmaceuticals Inc., SCYNEXIS Inc., Mycovia Pharmaceuticals Inc., NovaBiotics Inc., Matinas BioPharma Holdings Inc.

Read the full candidiasis therapeutics market report here:

https://www.thebusinessresearchcompany.com/report/candidiasis-therapeutics-global-market-report

Which Region Is Forecast To Lead The Candidiasis Therapeutics Market In Terms Of Market Size?

North America was the largest region in the candidiasis therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the candidiasis therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Candidiasis Therapeutics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=13182&type=smp

Browse Through More Reports Similar to the Global Candidiasis Therapeutics Market 2026, By The Business Research Company

High Level Disinfection Services Global Market Report

https://www.thebusinessresearchcompany.com/report/high-level-disinfection-services-global-market-report

Uv Disinfection Equipment Global Market Report

https://www.thebusinessresearchcompany.com/report/uv-disinfection-equipment-global-market-report

Pseudomonas Aeruginosa Infection Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/pseudomonas-aeruginosa-infection-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795